

**HIV I-Base**  
**(A company limited by guarantee)**

**REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2025**

**Charity No: 1081905**  
**Company No: 03962064**

## **HIV I-Base**

### **Contents**

|                                   | Page    |
|-----------------------------------|---------|
| Report of the trustees            | 1 – 8   |
| Independent examiner's report     | 9       |
| Statement of financial activities | 10      |
| Balance sheet                     | 11      |
| Cash Flow Statement               | 12      |
| Notes to the financial statements | 15 – 21 |

## **HIV I-Base**

### **Report of the trustees**

**Year ended 31 MARCH 2025**

---

#### **REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

03962064

**Registered Charity number**

1081905

**Registered office**

2<sup>nd</sup> Floor, Regis House  
45 King William Street  
London  
EC4R 9AN

**Trustees**

H Mhereza-Mitchell  
W F M Stokes  
C Decle

**Independent examiner**

J Howard FCA  
Azets Audit Services Limited  
2<sup>nd</sup> Floor, Regis House  
45 King William Street  
London  
EC4R 9AN

**Bankers**

National Westminster Bank plc  
PO Box 83  
Tavistock House  
Tavistock Square  
London  
WC1H 9JA

**Key management personnel as at 31 March 2025**

Simon Collins

## HIV I-Base

### Report of the trustees

#### Year ended 31 MARCH 2025

---

The trustees, who are also directors of the charity for the purpose of the Companies Act 2006, present their report with financial statements of charity for the year end 31 March 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

### OBJECTIVES AND ACTIVITIES

The objectives of the charity are the protection and preservation of public health and for the relief of sickness by disseminating to general practitioners and other health care professionals, the results of research and other information concerned with the causes, the transmission and the treatment of Human Immunodeficiency Virus (HIV), and related conditions so as to improve the treatment of people living with HIV and prevent the transmission of HIV and related conditions; by providing information, advice and other assistance to those with HIV or related conditions and to their families and carers and to benefit individuals, both nationally and internationally; through dissemination of up-to-date medical and social information related to the treatment and prevention of HIV and other related health issues.

A commitment to the public benefit within the objectives and activities of the organisation includes a belief that:

- People living with HIV who understand HIV treatment and prevention are more likely to be adherent to and benefit from these strategies.
- People living with HIV on successful treatment can lead working lives and contribute to society in many ways.
- People living with HIV with undetectable viral load on treatment have a zero risk of transmitting HIV their partners and almost zero risk of transmitting HIV to their infants (in the case of mothers with HIV) – giving enormous benefit to individuals and public health.
- HIV negative people can also use antiretrovirals to reduce their risk of becoming HIV positive – also conferring benefits to individuals and public health.

The charity activities to achieve these objectives include the following projects.

- HIV Treatment Bulletin (HTB), a technical review of the latest medical research aimed at doctors and other healthcare professionals and distributed by email and online.
- A range of non-technical treatment guides, with easy-to-understand information for people living with HIV and people at risk of HIV. Distribution is online and in printed format to individuals, HIV clinics and community organisations. These are regularly updated.
- An open-access free treatment information service by email, post and telephone and online, answering more than 5,000 questions each year.
- A website broadening access to our publications and archives and publicising our activities. All publications are available online as html pages and PDF format.
- Working with researchers as community representatives and advisors.
- National and international advocacy work including, policy and technical input to treatment and prevention guidelines, clinical trials and drug development. We serve on community advisory boards, guideline writing groups and trial steering committees to ensure that the needs of people living with HIV are represented.
- Engaging with national and international research groups and guidelines panels.

As part of restructuring this year, these projects were completed during the year and are no longer active.

- Fit for Purpose – a review of the latest research and developments in optimised HIV treatment for low- and middle-income countries (LMICs).
- Modern ART for South Africa – treatment and research information for activists from South Africa – including printed materials, app, website, videos and training.
- A series of small A7 pocket leaflets with less text than the guides, also distributed free to HIV clinics.
- UK CAB community network to provide education training for people living with HIV and their advocates.
- Supporting AfroCAB to develop a similar community network to UKCAB across several African countries.

## **HIV i-Base**

### **Report of the trustees**

**Year ended 31 MARCH 2025**

---

#### **ACHIEVEMENT AND PERFORMANCE**

##### **Review of activities**

HIV i-Base is a treatment activist group, led by people living with HIV and committed to providing timely HIV treatment information both to healthcare professionals and to people living with HIV and their advocates. HIV i-Base was formed in March 2000 and has continued to report the most innovative and important medical advances in HIV/AIDS.

2025 is our 26th year as a charity.

##### **HIV i-Base Projects**

###### **Publications**

During the period, we continued to produce HIV Treatment Bulletin (HTB), and our community publications. HTB is now a news stream rather than a compiled monthly publication. It is supported by alerts for the most important reports on social media platforms.

HTB is distributed to approximately 1600 email subscribers, with articles also distributed in email bulletins to roughly 1000 members of CHIVA and BHIVA. It is also accessed directly from the i-Base website. Articles are also publicised on social media.

We continued distributing the remaining printed stocks of the non-technical guides but also made decided to primarily focus on online publishing. Although sexual health clinics still value and want printed resources, these have become increasingly difficult to fund. This decision is also related to i-Base moved from a physical to a virtual working office. One exception is the UK Guide to PrEP which, thanks to a small grant, will continue to be printed and distributed free to clinics.

Although remaining print stocks of treatment guides were distributed until August, demand for publications still continued. We met this need by distributing posters and post-cards with QR codes but continue to fundraise for some print resources including the UK guide to PrEP. This year the PrEP guide was particularly important for reporting planned updates to the UK PrEP guidelines. A print run of 20,000 of these guides was distributed to UK clinics between April and August. From September to March we distributed 500 A4 posters and 8000 A6 postcards that included QR codes to this online guide.

All the key guides continue to be routinely updated online.

###### **Support to clinical research and community outreach**

###### **Community involvement in clinical research**

Several staff continued to be involved as community representatives with several research groups, including on guidelines panels, trial steering committees and advisory boards.

This involvement helps bridge the gap between researchers and the communities that their research is hoping to benefit. We help ensure greater awareness of the issues that affect each group and active involvement of other community advocates in these networks.

This area has increased in recent years and includes involvement in a number of important international studies. This has also been one of the key aims for the UK-CAB.

During 2024-25, advocates at i-Base were involved in the Dolphin 1 and 2 studies, ODYSSEY study, the INSIGHT network, International AIDS Society (IAS) Cure Working Group, Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP), the POPPY study, Public Health England (PHE), UK-CHIC Database, UK Drug Resistance Database, the RIO Study (cure-related research using bNAbs), the SWIFT study (with semaglutide) and the Liverpool University Drug Interaction website.

We were also involved in the CADO and PADO (adult and paediatric treatment optimisation groups), the AWG, PAWG (adult and paediatric antiretroviral working groups) and HIV pregnancy working groups and of the WHO HIV department.

## **HIV i-Base**

### **Report of the trustees**

**Year ended 31 MARCH 2025**

---

#### **ACHIEVEMENT AND PERFORMANCE – continued**

We informally supported other research groups with advice on participant information material and study design.

i-Base advocates were also involved as community representatives or in formally commenting on national and international guidelines panels including this year the European HIV lymphoma guidelines.

i-Base advocates are usually contributing authors on more than 20 peer-reviewed papers or conference presentations each year.

#### **Meetings, workshops and training UK**

We continued to run treatment workshops with community groups in the UK including as part of the UK-CAB programme.

#### **The UK-CAB**

i-Base founded the UK-CAB in 2002 and continued to provide administrative support for more than 20 years. This has been a highly successful project and now connects more than 700 advocates, broadly reflecting the UK demographics. Approximately 40% of members are women and 40% are from migrant populations.

Part of restructuring i-Base this year involved finding a new organisation to provide administrative support for the UK-CAB. We were very lucky to transfer the UK-CAB to Positively UK at the end of August 2025. We were able to do this with the active support of the UK-CAB chair, steering group and wider membership.

i-Base are proud of the role we have had to develop and support the UK-CAB for so long and we are very happy and confident that it will continue to be a vibrant and essential organisation with Positive UK.

#### **UK-CAB meetings**

i-Base organised two UK-CAB training meetings this year in May and August before the handover.

May 2024 – UK-CAB meeting after the BHIVA Spring Conference (Birmingham)

August 2024 – Cognitive impairment, ViV Healthcare and IAS 2024 conference feedback (London)

All presentations and materials from these meetings are online:

<https://ukcab.net/meetings/past-meetings-archive/>

#### **UK-CAB forum**

From April to August 2024, the members forum continued to be a focus for discussions on a wide range of treatment related topics. The CAB also co-ordinated wider community responses to the approval process for new drug approvals and developing topics for the community sessions at the BHIVA conference.

Forum discussions covered all aspects of HIV care including treatment updates and questions, HIV cure research including the RIO and other studies, conferences, webinars and other HIV online training announcements and changes in the CAB structure and the handover to Positive UK.

#### **UK-CAB and community representation**

UK-CAB provides a unique collective community voice and broad range of lived expertise from many different communities. We have a constituent network to represent and report to. We ensure transparency with the wider community and over the years many doctors, researchers and policy makers actively seek community views from the UK-CAB.

Members have also been on several writing groups and taken a lead role in the production of the non-technical summaries for these guidelines. We also mentor several new writing group representatives.

Information on this programme:

<http://www.ukcab.net/about/community-representatives/>

## **HIV i-Base**

### **Report of the trustees**

**Year ended 31 MARCH 2025**

---

#### **ACHIEVEMENT AND PERFORMANCE – continued**

Full list of UK-CAB community representatives:

<https://ukcab.net/community-representation/community-representatives/>

#### **UK-CAB collaborations**

UK-CAB works with professional bodies. These include:

British HIV Association (BHIVA).

National HIV Nurses Association (NHVNA).

A wide range of NHS HIV clinics.

NICE (National Institute for Health & Care Excellence).

Medical Research Council Clinical Trials Unit.

Medicines and Healthcare products Health Regulatory Agency.

Various clinical trial steering committees with National Institute of HIV Research, universities and other bodies.

#### **International training and transition to African organisations**

After more than a decade of close collaborations, i-Base wound down involvement in a major project that developed and updated community materials in the Modern ART for Africa series. This project supported the introduction of optimised antiretroviral treatment in low- and middle-income countries.

It included print, website and other resources that continued to be developed and updated.

<https://modernartforsouthafrica.co.za>

During 2024, as part of the long-term goal to transition this project to organisations based in South Africa, the Modern ART project was passed to Ezintsha who will continue to develop this work in partnership with the Treatment Action Campaign

#### **Website and Q&A services**

The i-Base website continued to generate high levels of use with approximately 200,000 to 300,000 web visits each month, roughly individual 3 million hits over the year. These figures vary as the algorithms used by search engines including Google are continually being updated.

The website continues to be assessed by people from more than 100 countries and territories globally. The countries with highest use were South Africa (25%), India (17%), USA (12%), UK (10%) and Nigeria, Kenya and Uganda (each with 7-8%).

From April 2024 to March 2025, the Q&A service responded to 7479 questions, with roughly 4960 email requests and 2519 online comments. This was roughly a 10% increase on the previous year and this is the third consecutive year that demand has increased.

All information is monitored and logged anonymously and the regional distribution for the service remains similar to previous years: approximately 10% are from the UK and 90% are international.

The distribution of issues remains similar with roughly half the enquiries linked to HIV prevention with 30% covering testing and transmission and 17% on PEP and PrEP. Although our primary focus is on treatment and care for people living with HIV, the increasing use of the same drugs for HIV prevention means that we also respond to these questions.

## **HIV i-Base**

### **Report of the trustees**

**Year ended 31 MARCH 2025**

---

#### **ACHIEVEMENT AND PERFORMANCE – continued**

The main treatment-related issues raised in emails, each accounted for about 4 to 7% of enquiries.

- Pregnancy, breast feeding and infant prophylaxis
- Treatment including access and starting treatment.
- Adherence and resistance
- Drug interactions
- CD4 count, viral load and U=U
- New diagnosis, symptoms and healthy lifestyle
- Side effects
- Disclosure and serodifferent couples

This service is supported by grants from Gilead Sciences and ViiV Healthcare.

#### **Website/IT**

All i-Base publications continue to be published on the website and our online Q&A answered several thousand of questions and online comments this year.

The website was accessed by around 3 million people from 6.5 million hits. The site has been accessed by people from 230 of the world's 241 countries and territories. It was designed and updated to have fast access even with dial-up or unreliable access to the Internet, including on mobile phones and tablets.

The website is continually updated to be match guidelines for access on handheld devices.

#### **FINANCIAL REVIEW**

i-Base has a policy of maintaining unrestricted funds, which are the free reserves of the charity, at a level, which equates to approximately three-months total expenditure. At the year end the free reserves exceeded this.

During the first half of the financial year, we worked on restructured i-Base to run on a minimal budget. This included changes in staffing, income and running costs. For roughly the first six months, i-Base continued some existing services while winding down and handing over others. Many staff wanted to either retire or focus on other activities and we worked with an independent consultant to support transitioning to other organisations or arranging planned managed redundancies.

For the second six months, i-Base moved to a minimal emergency budget in order to establish a more secure long-term basis for the organisation. This included giving up the rented office, reducing print resources and moving to volunteer rather than paid staff. This was also in response to the restrictions funding support similar to many other organisations in the HIV sector.

As a result, i-Base has continued many of the projects above on a much reduced budget but also established a model that should sustain web-based services for at least the next two years.

The Trustees are pleased to report that during the year to 31 March 2025 i-Base successfully transitioned the African support projects and the UK-CAB to new organisations. This included transferring any ring-fenced funding for the remainder of any grant period.

The direct information services (excluding publications) and the educational meetings for the UK-CAB were supported by several grants from pharmaceutical companies totalling £24,183 from Gilead Sciences and ViiV Healthcare. This support is always independent of editorial content and programming which remains separate from these awards.

Unrestricted funding for core costs remains difficult to secure and has been one of the main risks to the charity in recent years. For example, i-Base hasn't received statutory funding



## **HIV i-Base**

### **Report of the trustees**

**Year ended 31 MARCH 2025**

---

#### **FINANCIAL REVIEW – continued**

for many years and is unlikely to do so in the near future. However, cuts in NHS and Public Health England funding means less support for people living with HIV and related infections from social services. This is reflected in an **HIV i-Base**

increase demand for our information services and publications. i-Base also tends to quickly respond to the need for new resources, irrespective of whether these are specifically funded.

This included COVID-19 and mpox in recent years and this year it involved responding to dramatic changes in the US policy on international aid, including PEPFAR, since 20 January 2025. This led to i-Base being active in several international networks, including providing information to more safely manage the difficulties of closed sexual health clinic and uncertain access to ART. We worked closely with WHO for online information and webinars and worked with researchers on future management options including the potential for less than daily dosing.

Support from pharmaceutical companies is dependent on the priorities and governance of the individual companies and we are lucky that two of the leading companies value and support our work.

These funding issues have always been the case and over the last 20 years there has been sufficient flexibility for some level of support to contribute towards our work. Most notably, the number of companies in the field and their community budgets have both decreased.

We still continue to apply for funding from a wider range of sources whenever this is in line with our objectives.

Total income for this year was £67,757 compared to £315,715 in the previous year.

Net resources expended for the year amounted to £299,973 compared to £ 496,183 in the previous year.

Year end results show a deficit of £232,216.

#### **FUTURE PLANS**

i-Base was founded in 2000 to fill a gap that wasn't being met by existing HIV services and organisation in the UK. Since then, we have continued to focus on projects related to the evolving science being HIV treatment from an activist and peer-led perspective.

We still focus on providing specialised treatment information that makes us an internationally recognised and trusted community organisation. We have never been interested in duplicating anything that is already being produced.

Even running on a reduced budget, our services and perspectives are unique and enable us to effectively support and influence the work of others.

Although based in the UK, i-Base has always actively linked with similar HIV organisations in other countries and regions.

We hoped that restructuring i-Base and moving to an emergency budget will enable the project to continue into the future.

## **HIV i-Base**

### **Report of the trustees**

**Year ended 31 MARCH 2025**

---

#### **STRUCTURE, GOVERNANCE AND MANAGEMENT**

##### **Status**

HIV i-Base is a charitable company limited by guarantee, incorporated on 28 March 2000 and registered as a charity on 8 August 2000.

The financial statements comply with current statutory requirements, the Memorandum and Articles of Association and the Statement of Recommended Practice – Accounting and Reporting by Charities.

##### **Trustees**

A new Trustee, Mr Christian Declé, was recruited in May 2024. The board of Trustees are listed on page 1.

Trustees have a personal connection and interest in i-Base's work as well as some experience of charity governance.

An induction pack is provided for new Trustees, and they are invited to meetings and events organised by the organisation and to develop involvement in all our work.

##### **Management**

i-Base has a policy that reviews salaries on an annual basis following annual staff reviews.

Although staffing is now reduced the organisation will link any future salaries to NJC salary scales

##### **Risk Management**

As part of the annual planning process, the trustees identify the major risks (financial, operational, governance/compliance and external risks) facing the Charity over the coming year.

Each risk is assessed according to the likelihood, and potential impact, and systems and procedures are agreed to manage those risks which are implemented by the trustees and staff.

Some of the main risks facing the charity are detailed below and how these risks are being contained:

- Fundraising for unrestricted funds. Mitigation includes a focus on developing new income streams and relationships and close monitoring of income and expenditure. Moving to a reduced budget means that the remaining risks in this category are assessed as medium. This is in spite of reduced funding opportunities.
- Moving to a virtual office space from 1 September 2024 significantly reduced running costs.

Approved by order of the board of trustees on ..... and signed on its behalf by:

.....

**W F M Stokes**

## **HIV I-Base**

### **Independent examiner's report**

#### **Year ended 31 MARCH 2025**

---

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2025, which are set out in the attached Statement of Financial Activities, the Balance Sheet and the related notes.

#### **Responsibilities and basis of report**

As the trustees of the charitable company (and also its directors for the purposes of company law), you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006.

Having satisfied myself that the financial statements of the charitable company are not required to be audited under Part 16 of the Companies Act 2006 and are eligible for independent examination, I report in respect of my examination of the charitable company's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

#### **Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charitable company as required by section 386 of the Companies Act 2006;
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the Companies Act 2006 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

**J Howard FCA**  
**Azets Audit Services**  
2<sup>nd</sup> Floor, Regis House,  
45 King William Street  
London,  
EC4R 9AN

Date

## HIV I-Base

### Statement of financial activities (incorporating an income and expenditure account)

Year ended 31 MARCH 2025

|   | Notes | Unrestricted<br>Funds<br>£ | Restricted<br>Funds<br>£ | Total<br>2025<br>£ | Total<br>2024<br>£ |
|---|-------|----------------------------|--------------------------|--------------------|--------------------|
| <b>Income:</b>  |       |                            |                          |                    |                    |
| Donations and legacies                                | 2     | 9,934                      | 55,627                   | 65,561             | 310,719            |
| Investment income                                     | 3     | 2,196                      | -                        | 2,196              | 4,996              |
| <b>Total income</b>                                   |       | <b>12,130</b>              | <b>55,627</b>            | <b>67,757</b>      | <b>315,715</b>     |
| <b>Expenditure:</b>                                   |       |                            |                          |                    |                    |
| Raising funds   | 4     | 4,909                      | -                        | 4,909              | 28,306             |
| Charitable activities                                 | 5     | 209,158                    | 85,906                   | 295,064            | 467,877            |
| <b>Total resources expended</b>                       | 6     | <b>214,067</b>             | <b>85,906</b>            | <b>299,973</b>     | <b>496,183</b>     |
| <b>Net income/(expenditure) before transfers</b>      |       | <b>(201,937)</b>           | <b>(30,279)</b>          | <b>(232,973)</b>   | <b>(180,468)</b>   |
| Transfers between funds                               |       | -                          | -                        | -                  | -                  |
| <b>Net movement in funds</b>                          |       | <b>(201,937)</b>           | <b>(30,279)</b>          | <b>(232,973)</b>   | <b>(180,468)</b>   |
| Fund balances brought forward                         |       | 306,697                    | 30,771                   | 337,468            | 517,936            |
| <b>Fund balances carried forward at 31 MARCH 2025</b> | 12    | <b>104,760</b>             | <b>492</b>               | <b>105,252</b>     | <b>337,468</b>     |

The notes on pages 13 to 21 form part of these financial statements.

## HIV I-Base

### Balance Sheet

As at 31 MARCH 2025

|   | Notes | £              | 2025 | £              | £              | 2024 | £              |
|---|-------|----------------|------|----------------|----------------|------|----------------|
| <b>Fixed assets</b>                                   |       |                |      |                |                |      |                |
| Tangible fixed assets                                 | 9     |                |      | 2,451          |                |      | 4,089          |
| <b>Current assets</b>                                 |       |                |      |                |                |      |                |
| Debtors   | 10    | 11,436         |      |                | 26,970         |      |                |
| Cash at bank and in hand                              |       | 110,072        |      |                | 358,426        |      |                |
|   |       | <u>121,508</u> |      |                | <u>385,396</u> |      |                |
| <b>Creditors:</b> Amounts falling due within one year | 11    | (18,707)       |      |                | (52,017)       |      |                |
| <b>Net current assets</b>                             |       |                |      | 105,801        |                |      | 333,379        |
| <b>Net assets</b>                                     |       |                |      | <u>105,252</u> |                |      | <u>337,468</u> |
| <b>Funds</b>  |       |                |      |                |                |      |                |
| Restricted funds                                      |       |                |      | 492            |                |      | 30,771         |
| Unrestricted funds                                    |       |                |      | 104,760        |                |      | 306,697        |
|   | 13    |                |      | <u>105,252</u> |                |      | <u>337,468</u> |

The company is entitled to exemption from audit under section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- Ensuring that the company keeps accounting records which comply with section 386 and 387 of the companies Act 2006 and
- Preparing financial statements which give a true and fair view of the statement of affairs of the company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the special provisions of Part 15 of Companies Act 2006 relating to small companies.

Approved by the Board on ..... and signed on their behalf by:

.....

**W F M Stokes**

The notes on pages 13 to 21 form part of these financial statements

**HIV I-Base****Statement of Cash Flows****As at 31 MARCH 2025**

|   | Note | 2025<br>£ | 2024<br>£ |
|---|------|-----------|-----------|
| <b>Cash flow from operating activities</b>                                | 17   | (250,550) | (168,776) |
| <b>Net cash flow from operating activities</b>                            |      | (250,550) | (168,776) |
| <b>Cash flow from investing activities</b>                                |      |           |           |
| Payments to acquire tangible fixed assets                                 |      | -         | (3,668)   |
| Interest received   |      | 2,196     | 4,996     |
| <b>Net cash flow from investing activities</b>                            |      | 2,196     | 1,328     |
| <b>Net increase / (decrease) in cash and cash equivalents</b>             |      | (248,354) | (167,448) |
| <b>Cash and cash equivalents at the beginning of the reporting period</b> |      | 358,426   | 525,874   |
| <b>Cash and cash equivalents at the end of the reporting period</b>       |      | 110,072   | 358,426   |
| <b>Cash and cash equivalents consists of:</b>                             |      |           |           |
| Cash at bank and in hand  |      | 110,072   | 358,426   |
| <b>Cash and cash equivalents at end date 2025</b>                         |      | 110,072   | 358,426   |

The notes on pages 13 to 21 form part of these financial statements

## HIV I-Base

### Notes to the financial statements

For the year ended 31 MARCH 2025

---

#### 1. Accounting policies

##### a) General information and basis of preparation

HIV I-Base is a company limited by guarantee in the United Kingdom. The liability of each member in the event of winding-up is limited to £10. The address of the registered office is given in the charity information on page 8 of these financial statements. The nature of the charity's operations and principal activities are set out on page 1.

The charitable company constitutes a public benefit entity as defined by FRS 102.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Practice as it applies from 1 January 2015.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are prepared in sterling which is the functional currency of the charity.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

##### b) Going Concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

##### c) Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for the particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

## Notes to the financial statements

## 1. Accounting policies - continued

All incoming resources are including in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that income will be received.

Donation income including grants; are recognised in full in the Statement of Financial Activities in the year in which they are receivable. Such income is only deferred when the donor specifies that the grant must only be used in future accounting periods. Grants received for specific purposes are treated as restricted funds.

Investment income is included when receivable.

All expenditure is accounted for on an accruals basis and has been classified under heading that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. The irrecoverable element of VAT is included with the item of expenses to which it relates. It is categorised under the following headings:

Costs of raising funds are those costs incurred in attracting grants and donation income.

Charitable expenditure comprise of those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs allocated directly to such activities and those costs of an indirect nature necessary to support them.

Staff costs are allocated between costs headings according to the function of each employee.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include governance costs, administrative office function costs, depreciation and premises costs. They are incurred directly in support of expenditure on the objects of the charitable company.

Governance costs comprise all costs involving the public accountability of the charity and include statutory independent examination fees.

Support and Governance costs have been allocated across the charitable activities using various percentage allocations.

**Tangible fixed assets**  
Tangible fixed assets are stated at cost less accumulated depreciation

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost of each asset over their estimated useful lives as follows:

|                  |                            |
|------------------|----------------------------|
| Office equipment | 40% reducing balance basis |
|------------------|----------------------------|

**Individual** fixed assets costing £200 or more are capitalised at cost.

Grants repayable and other debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.



## HIV I-Base

### Notes to the financial statements

#### For the year ended 31 MARCH 2025

---

**1. Accounting policies - continued**

**i) Cash at bank and in hand**

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from date of acquisitions or opening of the deposit or similar account.

**j) Creditors**

Creditors are recognised when there is a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

Other creditors and accruals are recognised at their settlement amount due.

**k) Financial instruments**

The charity only has assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**l) Operating leases**

Rentals payable under operating leases are charged to the Statement of Financial Activities as incurred over the term of the lease

**m) Foreign currency**

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. All exchange differences are reflected in the Statement of Financial Activities.

**n) Tax**

The charitable company is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part II Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

**o) Pensions**

The charity contributes to a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the Charity in independently administered funds. The pension cost charge represents contributions payable by the Charity to the scheme.

## HIV I-Base

### Notes to the financial statements

#### For the year ended 31 MARCH 2025

**p) Judgements and key sources of estimation uncertainty**

Accounting estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The following judgements (apart from those involving estimates) have been made in the process of applying the above accounting policies that have had the most significant effect on amounts recognised in the financial statements:

*Useful economic lives of tangible assets*

The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 9 for the carrying amount of the property, plant and equipment, and note g for the useful economic lives for each class of assets.

There are no key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

| <b>2. Donations and legacies</b>                               | <b>Unrestricted<br/>2025<br/>£</b> | <b>Restricted<br/>2025<br/>£</b> | <b>Total<br/>2025<br/>£</b> | <b>Total<br/>2024<br/>£</b> |
|--|------------------------------------|----------------------------------|-----------------------------|-----------------------------|
| Individual, charitable, corporate and international donations. | 9,934                              | 55,627                           | <b>65,561</b>               | 310,719                     |
|  | <u>9,934</u>                       | <u>55,627</u>                    | <u><b>65,561</b></u>        | <u>310,719</u>              |

In 2024, £155,832 of the donations and legacies income was attributable to the restricted funds, and the remaining £154,887 was attributable to the unrestricted funds.

| <b>3. Investment income</b> | <b>Unrestricted<br/>2025<br/>£</b> | <b>Restricted<br/>2025<br/>£</b> | <b>Total<br/>2025<br/>£</b> | <b>Total<br/>2024<br/>£</b> |
|-----------------------------|------------------------------------|----------------------------------|-----------------------------|-----------------------------|
| Bank interest               | 2,196                              | -                                | <b>2,196</b>                | 4,996                       |
|                             | <u>2,196</u>                       | <u>-</u>                         | <u><b>2,196</b></u>         | <u>4,996</u>                |

In 2024, all £4,996 of the investment income was attributable to the unrestricted funds.

| <b>4. Raising funds</b>             | <b>Unrestricted<br/>2025<br/>£</b> | <b>Restricted<br/>2025<br/>£</b> | <b>Total<br/>2025<br/>£</b> | <b>Total<br/>2024<br/>£</b> |
|-------------------------------------|------------------------------------|----------------------------------|-----------------------------|-----------------------------|
| Cost of generating voluntary income | 4,909                              | -                                | <b>4,909</b>                | 28,306                      |
|                                     | <u>4,909</u>                       | <u>-</u>                         | <u><b>4,909</b></u>         | <u>28,306</u>               |

In 2024, all £28,306 of the cost of raising funds was attributable to the unrestricted funds.

## HIV I-Base

### Notes to the financial statements

#### For the year ended 31 MARCH 2025

| 5. Charitable activities           | Unrestricted<br>2025<br>£ | Restricted<br>2025<br>£ | Total<br>2025<br>£ | Total<br>2024<br>£ |
|------------------------------------|---------------------------|-------------------------|--------------------|--------------------|
| Information services               | 121,516                   | 8,863                   | 130,579            | 184,917            |
| UKCAB                              | -                         | 77,010                  | 77,010             | 35,688             |
| Research and community development | 87,441                    | -                       | 87,441             | 247,107            |
| AFROCAB                            | -                         | 33                      | 33                 | 165                |
| Rainwater                          | -                         | -                       | -                  | -                  |
|                                    | <u>209,157</u>            | <u>85,906</u>           | <u>295,063</u>     | <u>467,877</u>     |

In 2024, £166,302 of the expenditure in relation to charitable activities was attributable to the restricted fund, with the remaining £301,575 being attributable to the unrestricted fund.

| 6. Analysis of expenditure           | Direct<br>Costs<br>£ | Support<br>Costs<br>(note 6.1)<br>£ | Total<br>2025<br>£ | Total<br>2024<br>£ |
|--------------------------------------|----------------------|-------------------------------------|--------------------|--------------------|
| Costs of generating voluntary income | -                    | 4,909                               | 4,909              | 28,306             |
| Information services                 | 21,610               | 108,969                             | 130,579            | 184,917            |
| UKCAB                                | 31,208               | 45,802                              | 77,010             | 35,688             |
| Research and community development   | 1,730                | 85,711                              | 87,441             | 247,107            |
| AFROCAB                              | 33                   | -                                   | 33                 | 165                |
| Rainwater                            | -                    | -                                   | -                  | -                  |
|                                      | <u>54,581</u>        | <u>245,391</u>                      | <u>299,972</u>     | <u>496,183</u>     |

In 2024, £430,448 of expenditure was attributable to direct costs, with the remaining £65,735 being attributable to support costs.

| 6.1 Support costs                           | Total<br>2025<br>£ | Total<br>2024<br>£ |
|---|--------------------|--------------------|
| Bank charges                                | 365                | 497                |
| Communications                              | 606                | 1,925              |
| Computer costs                              | 2,455              | 2,808              |
| Consultancy                                 | 10,878             | 210                |
| Depreciation                                | 1,638              | 2,727              |
| Postage, stationery and sundries            | 8,702              | 2,953              |
| Rent, rates and insurance                   | 17,622             | 37,854             |
| Staff costs                                 | 196,336            | 1,652              |
| Subscriptions                               | 96                 | 96                 |
| Travel, subsistence & conference attendance | 13                 | 250                |
| <b>Governance costs:</b>                    |                    |                    |
| Accountancy costs                           | 3,430              | 7,203              |
| Independent examination                     | 3,250              | -                  |
| Auditors remuneration                       | -                  | 7,560              |
|   | <u>245,391</u>     | <u>65,735</u>      |

## HIV I-Base

### Notes to the financial statements

#### For the year ended 31 MARCH 2025

---

##### 7. Staff costs and remuneration

|  | 2025           | 2024           |
|--|----------------|----------------|
|  | £              | £              |
| Gross wages and salaries                         | 124,883        | 218,896        |
| Employer's national insurance costs              | 8,991          | 17,676         |
| Pension Contributions                            | 3,511          | 8,799          |
|  | <u>137,385</u> | <u>245,371</u> |
|  | Number         | Number         |
| The average number of employees during the year  |                |                |
| Calculated on a full time equivalent basis, was: | <u>6</u>       | <u>6</u>       |

One employee received remuneration amounting to more than £60,000 in the year (2024: two).

Trustees received no remuneration and were not reimbursed for any of their expenses in the year.

As of 31 March 2025, the key management of the charitable company comprise one of the co-founders.

The total employee benefits of the key management personnel of the charitable company were £122,068 (2024: £202,469).

##### 8. Net incoming/(outgoing) resources for the year

|   | 2025          | 2024          |
|---|---------------|---------------|
|   | £             | £             |
| This is stated after charging:              |               |               |
| Depreciation                                | 1,638         | 2,727         |
| Auditors' remuneration – audit services     | -             | 7,560         |
| Auditors' remuneration – non audit services | -             | 1,926         |
| Independent examination                     | 3,250         | -             |
| Operating lease rentals – property          | <u>11,750</u> | <u>23,500</u> |

# HIV I-Base

## Notes to the financial statements

For the year ended 31 MARCH 2025

|     |   |                           |                         |
|-----|---|---------------------------|-------------------------|
| 9.  | <b>Tangible fixed assets</b>                          |                           | <b>Office equipment</b> |
|     | <b>Cost</b>   |                           | <b>£</b>                |
|     | At 1 April 2024                                       |                           | 36,609                  |
|     | Additions   |                           | -                       |
|     | Disposal  |                           | -                       |
|     | At 31 MARCH 2025                                      |                           | 36,609                  |
|     | <b>Depreciation</b>                                   |                           |                         |
|     | At 1 April 2024                                       |                           | 35,520                  |
|     | Charge for the year                                   |                           | 1,638                   |
|     | Disposal  |                           | -                       |
|     | At 31 MARCH 2025                                      |                           | 34,158                  |
|     | <b>Net book value</b>                                 |                           |                         |
|     | At 31 MARCH 2025                                      |                           | 2,451                   |
|     | At 31 March 2024                                      |                           | 4,089                   |
| 10. | <b>Debtors</b>  |                           |                         |
|     |   | <b>2025</b>               | <b>2024</b>             |
|     |   | <b>£</b>                  | <b>£</b>                |
|     | Grants repayable                                      | 2,500                     | 15,818                  |
|     | Prepayments and accrued income                        | 8,145                     | 10,420                  |
|     | Other debtors   | 791                       | 732                     |
|     |   | 11,436                    | 26,970                  |
| 11. | <b>Creditors: amounts falling due within one year</b> |                           |                         |
|     |   | <b>2025</b>               | <b>2024</b>             |
|     |   | <b>£</b>                  | <b>£</b>                |
|     | Amounts payable                                       | -                         | 9,163                   |
|     | Taxation and social security                          | -                         | 6,204                   |
|     | Other creditors                                       | -                         | 3,177                   |
|     | Accruals and deferred income (note 11.1)              | 18,707                    | 33,473                  |
|     |   | 18,707                    | 52,017                  |
| 12. | <b>Analysis of net assets between funds</b>           |                           |                         |
|     |   | <b>Unrestricted funds</b> | <b>Restricted funds</b> |
|     |   | <b>£</b>                  | <b>£</b>                |
|     | Tangible fixed assets                                 | 2,451                     | -                       |
|     | Current assets  | 121,016                   | 492                     |
|     | Current liabilities                                   | (18,707)                  | -                       |
|     |   | 104,760                   | 492                     |
|     |   |                           | 105,252                 |

## HIV I-Base

### Notes to the financial statements

For the year ended 31 MARCH 2025

#### 13. Statement of funds

|                                     | 1 April<br>2024<br>£ | Incoming<br>resources<br>£ | Resources<br>expended<br>£ | Transfer<br>£ | 31 MARCH<br>2025<br>£ |
|-------------------------------------|----------------------|----------------------------|----------------------------|---------------|-----------------------|
| <b>Restricted funds</b>             |                      |                            |                            |               |                       |
| AFROCAB                             | 33                   | -                          | (33)                       | -             | -                     |
| UKCAB                               | 30,271               | 46,739                     | (77,010)                   | -             | -                     |
| Information services                | 467                  | 8,888                      | (8,863)                    | -             | 492                   |
| Research & community<br>development | -                    | -                          | -                          | -             | -                     |
| <b>Unrestricted funds</b>           |                      |                            |                            |               |                       |
| General                             | 306,697              | 12,130                     | (214,067)                  | -             | 104,760               |
| <b>Total Funds</b>                  | <b>337,468</b>       | <b>67,757</b>              | <b>(299,973)</b>           | <b>-</b>      | <b>105,252</b>        |

#### AFROCAB:

Funds held on behalf of Afrocab relate to grants made to Afrocab by various donors to enable them to establish a network of HIV positive people and advocates across Sub-Saharan Africa based loosely on the UKCAB network established in the UK by HIV I-Base. The group organises meetings on HIV treatment, access to treatment and other topics as well as working with international organisations such as the WHO to canvas opinions from HIV positive people and advocates.

#### UKCAB:

Restricted funds relating to the UKCAB are those donated by a number of donors for the specific purpose of covering attendance costs at UKCAB meetings for those delegates from outside London. These include travel, accommodation and other expenses such as childcare costs.

#### Research & community development:

Restricted funds relating to Community Outreach Overseas are those granted by WITS RH and HIV Institute for the specific purpose of covering costs relating to publications such as print and design costs, travel to meetings, accommodation and other expenses such as ground transport.

## HIV I-Base

### Notes to the financial statements

#### For the year ended 31 MARCH 2025

##### 13.1 Statement of funds – Prior year

|                                     | 1 April<br>2022<br>£ | Incoming<br>resources<br>£ | Resources<br>expended<br>£ | Transfer<br>£ | 31 March<br>2024<br>£ |
|-------------------------------------|----------------------|----------------------------|----------------------------|---------------|-----------------------|
| <b>Restricted funds</b>             |                      |                            |                            |               |                       |
| AFROCAB                             | 33                   | -                          | -                          | -             | 33                    |
| UKCAB                               | 40,741               | 25,218                     | (35,688)                   | -             | 30,271                |
| Information services                | 467                  | 44,535                     | (44,535)                   | -             | 467                   |
| Research & community<br>development | -                    | 86,079                     | (86,079)                   | -             | -                     |
| <b>Unrestricted funds</b>           |                      |                            |                            |               |                       |
| General                             | 476,695              | 159,883                    | (329,881)                  | -             | 306,697               |
| <b>Total Funds</b>                  | <b>517,936</b>       | <b>315,715</b>             | <b>(496,183)</b>           | <b>-</b>      | <b>337,468</b>        |

##### 14. Operating lease commitments

|   | 2025<br>£ | 2024<br>£     |
|---|-----------|---------------|
| The minimum annual rentals under operating leases are as follows: |           |               |
| Within one year   | -         | 13,583        |
| Between one and five years  | -         | -             |
|   | <u>-</u>  | <u>13,583</u> |

##### 15. Related party disclosure

There were no related party transaction for the current year or the prior years.

##### 16. Ultimate controlling party

The charitable company is considered to have no ultimate controlling party.

##### 17. Reconciliation of net income/(expenditure) to net cash flow from operating activities

|                                       | 2025<br>£        | 2024<br>£        |
|---------------------------------------|------------------|------------------|
| Net income/(expenditure) for year     | (232,216)        | (180,468)        |
| Interest receivable                   | (2,196)          | (4,996)          |
| Depreciation of tangible fixed assets | 1,638            | 2,727            |
| Disposal of tangible fixed assets     | -                | 51               |
| (Increase) / decrease in debtors      | 15,534           | (18,468)         |
| Increase / (decrease) in creditors    | (33,310)         | 32,378           |
|                                       | <u>(250,550)</u> | <u>(168,776)</u> |